News

Medigene announces Veregen® to be launched in the Czech Republic, Poland, Hungary, and Slovakia

  • Market launches to be initiated in Q1 2014
  • Veregen®, an extract of green tea leaves, included into new treatment guidelines for genital warts

Martinsried/Munich, 11 December 2013. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the market launch of Veregen® ointment for the treatment of genital warts in the East European countries the Czech Republic, Poland, Hungary, and Slovakia is scheduled to be initiated by the company's marketing partner NORDIC Pharma, s.r.o. in the first quarter 2014.

Professor Jana Hercogová, president of European Academy of Dermatology and Venereology (EADV) will introduce the new guidelines for the treatment of condylomata accuminata (genital warts) and inform about the new treatment options, including an extract of green tea leaves, during the Annual Congress of the Hungarian Dermatological Society in Budapest on December 14, 2013. NORDIC Pharma will have an exhibition booth to introduce Veregen® ointment (extract of green tea leaves) to the medical community.

Veregen® is already available in the USA, Germany, Austria, Switzerland, Spain, Serbia, the Netherlands and Taiwan. Market approvals for Veregen® have been granted in a number of other countries. Several marketing agreements have been concluded in Europe, Asia, and America. Medigene is planning to continue this global licensing strategy to further exploit the product's market potential.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

About NORDIC Pharma: The Nordic Group is a privately owned, fast-growing, fully integrated, pan-European Pharmaceutical Group with a strong emphasis on quality products and services that cater to the special needs of each client and patient. The Nordic Group originated in 1995 with the establishment of the first Nordic organisation in Scandinavia. In the years that followed, the Nordic Group gradually expanded its geographical implantation throughout Europe and significantly enlarged its range of activities. Today, the Nordic Group continues to capitalise on its existing platform of core competencies, products, services, and technologies to develop the company in two specialised segments of the pharmaceutical market: marketing and sales of specialty pharmaceuticals and specialised pharmaceutical services which focus on product development, manufacturing, supply logistics, and regulatory activities. For more information, please visit www.nordicpharmagroup.com.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from a marketed product, Veregen®, which is distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®; and is developing an innovative vaccine technology. Further information at www.medigene.com.

 

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to: www.medigene.de/unsubscribe